博安生物股东将股票由中国证券登记结算香港转入中信证券经纪香港 转仓市值5.12亿港元

Group 1 - The core point of the article is that BioNTech (06955) has transferred shares worth HKD 512 million, representing 8.76% of its market value, from China Securities Depository and Clearing Corporation Hong Kong to CITIC Securities Brokerage Hong Kong on January 13 [1] - On the same day, BioNTech announced that its self-developed drug BA6101 (60mg) has been approved for market launch by Bolivia's National Medicines and Health Technologies Agency (AGEMED) [1] - BA6101 is a biosimilar to the original drug Prolia, which is widely used globally for the treatment of osteoporosis [1]